For metastatic colorectal cancer that has progressed through fluoropyrimidine, oxaliplatin, and irinotecan, third-line treatment options include fruquintinib, regorafenib, trifluridine-tipiracil (with bevacizumab preferred), biomarker-directed therapies, or best supportive care, according to NCCN guidelines.
Fruquintinib plus trifluridine-tipracil demonstrated acceptable tolerability in clinical activity with a partial response rate of 10.9% and a median free progression survival of 6.4 months.
Trifluridine-tipiracil plus bevacizumab is the preferred regimen based on the SUNLIGHT trial, which demonstrated superior overall survival compared to trifluridine-tipiracil alone (10.8 vs 7.5 months).
The combination showed consistent benefit across subgroups, including patients previously treated with bevacizumab (median OS 9.0 months).
Network meta-analyses consistently rank trifluridine-tipiracil plus bevacizumab as the most effective third-line option.
Regorafenib, a multikinase inhibitor, improved median overall survival by 1.4 months compared to placebo in the CORRECT trial (6.4 vs 5.0 months).
The main toxicity is hand-foot syndrome (17%), often requiring dose escalation strategies starting at 80 mg daily.
Fruquintinib, a selective VEGFR inhibitor, demonstrated median OS of 7.4 months in the FRESCO-2 trial.
All three agents are listed as NCCN-recommended options for disease progressed through all available regimens.
Real-world data suggest comparable efficacy between regorafenib and trifluridine-tipiracil monotherapy, with median OS of 6.3 and 6.7 months respectively.
Sequential use of both agents may prolong survival, with some data suggesting regorafenib followed by trifluridine-tipiracil yields better progression-free survival (11.5 vs 8.5 months) compared to the reverse sequence.
Biomarker-Directed Therapies
Molecular profiling is critical in third-line settings to identify actionable alterations.
For KRAS/NRAS/BRAF wild-type tumors (particularly left-sided), anti-EGFR therapy with cetuximab or panitumumab ± irinotecan remains an option if not previously used.
For BRAF V600E mutations, encorafenib plus cetuximab or panitumumab is preferred, with phase 3 evidence showing superiority over FOLFIRI in second-line.
KRAS G12C mutations can be targeted with sotorasib or adagrasib combined with anti-EGFR therapy.
HER2-amplified tumors (3-5% of colorectal cancers) may benefit from trastuzumab-based combinations or fam-trastuzumab deruxtecan-nxki for IHC 3+ tumors.
Rare fusions including NTRK (larotrectinib, entrectinib, repotrectinib) and RET (selpercatinib) should be identified through comprehensive molecular testing.
Rechallenge with previously effective regimens is reasonable if therapy was discontinued for reasons other than progression (e.g., cumulative toxicity, treatment breaks).
For RAS wild-type patients who benefited from first-line anti-EGFR therapy, rechallenge after intervening therapy may provide benefit, though data are limited.
Modified FOLFIRINOX as a rescue regimen showed 60% disease control rate in a recent phase 2 trial of refractory patients.